In the UKPDS cohort, the development of eGFR 300 mg/g) as the main renal outcome and the other trials addressing also eGFR-related endpoints, RRT and renal death (Table 1) [11]
Average body weight reduction at 72 weeks in the SURMOUNT-1 trial
If you have issues like low blood sugar or stomach pain, your dose might need to be changed
Dontia Orey, Andrea Ashchi Lachapelle, Andrew Ashchi, Ariana Genovese, Jenna Jackson, Ramsey Ashchi, and Towfeeq Ashchi were involved in data curation, analysis, and writing
Tirzepatide has been shown to significantly lower HbA1c levels, which is a key marker of long-term blood sugar control
Full Article Over the past few years, there has been a rapid rise in the use of GLP-1-based medications for obesity and metabolic health